Diagonal Bio AB (ST:DIABIO) — Market Cap & Net Worth
Market Cap & Net Worth: Diagonal Bio AB (DIABIO)
Diagonal Bio AB (ST:DIABIO) has a market capitalization of $703.53K (Skr6.54 Million) as of August 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #30755 globally and #724 in its home market, demonstrating a -20.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Diagonal Bio AB's stock price Skr0.00 by its total outstanding shares 1634346705 (1.63 Billion). Review Diagonal Bio AB (DIABIO) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
Diagonal Bio AB Market Cap History: 2021 to 2025
Diagonal Bio AB's market capitalization history from 2021 to 2025. Data shows change from $927.53 Million to $703.53K (-82.60% CAGR).
Diagonal Bio AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Diagonal Bio AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
47.09x
Diagonal Bio AB's market cap is 47.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $927.53 Million | $407.00K | -$11.66 Million | 2278.94x | N/A |
| 2022 | $193.47 Million | $203.00K | -$16.16 Million | 953.05x | N/A |
| 2023 | $62.09 Million | $23.00K | -$11.68 Million | 2699.40x | N/A |
| 2024 | $2.92 Million | $62.00K | -$9.93 Million | 47.09x | N/A |
Competitor Companies of DIABIO by Market Capitalization
Companies near Diagonal Bio AB in the global market cap rankings as of August 4, 2026.
Key companies related to Diagonal Bio AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Diagonal Bio AB Historical Marketcap From 2021 to 2025
Between 2021 and today, Diagonal Bio AB's market cap moved from $927.53 Million to $ 703.53K, with a yearly change of -82.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr703.53K | -75.90% |
| 2024 | Skr2.92 Million | -95.30% |
| 2023 | Skr62.09 Million | -67.91% |
| 2022 | Skr193.47 Million | -79.14% |
| 2021 | Skr927.53 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Diagonal Bio AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $703.53K USD |
| MoneyControl | $703.53K USD |
| MarketWatch | $703.53K USD |
| marketcap.company | $703.53K USD |
| Reuters | $703.53K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Diagonal Bio AB
Diagonal Bio AB (publ) provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. The company offers LAMPlify, a system used to identify the presence of specific genetic markers, such as fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid an… Read more